Akebia Therapeutics (AKBA) Current Assets (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Current Assets data on file, last reported at $243.5 million in Q1 2026.

• On a quarterly basis, Current Assets rose 19.48% year-over-year to $243.5 million in Q1 2026; TTM through Mar 2026 was $243.5 million, a 19.48% increase from a year earlier, with the FY2025 full-year figure at $253.0 million, up 122.22% from the prior year.
• Current Assets for Q1 2026 stood at $243.5 million, down from $253.0 million in the prior quarter.
• Over the last five years, Current Assets for AKBA reached as high as $308.2 million in Q2 2022 and fell as low as $100.1 million in Q3 2024.
• Historically, Current Assets has averaged $184.7 million across 5 years, with a median of $185.2 million in 2022.
• Across the five-year window, Current Assets tumbled 61.57% in 2023 and jumped 158.03% in 2025, its largest moves.
• Year by year, Current Assets stood at $185.2 million in 2022, then sank by 36.2% to $118.1 million in 2023, then fell by 3.65% to $113.8 million in 2024, then soared by 122.22% to $253.0 million in 2025, then decreased by 3.75% to $243.5 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $243.5 million in Q1 2026, $253.0 million in Q4 2025, and $258.3 million in Q3 2025.